Is Ketamine Treatment Covered By Medicaid In New York? NYRx Guide

Dr. Pervaiz Qureshi

Internal Medicine Physician & Medical Director

[post-views]

Introduction

Finding affordable mental healthcare in New York can feel like navigating a maze, especially when traditional treatments fail. The question of, is ketamine treatment covered by Medicaid in New York, is among the most common ones we hear. The answer depends in part on the delivery method. While regulator-approved esketamine nasal spray (Spravato) is generally covered under the NYRx pharmacy program, intravenous (IV) ketamine infusions remain an out-of-pocket expense in 2026. Coverage rules vary meaningfully by plan and by treatment type, so we maintain a detailed ketamine therapy insurance coverage guide that covers Medicaid, Medicare, private insurance, HSA/FSA, superbill options, and out-of-network reimbursement scenarios.

Here we look at the cost implications of ketamine therapy for major depressive disorder (MDD), particularly treatment-resistant depression (TRD), in New York. Aside from asking about its effectiveness, patients want to know whether or not ketamine treatment is covered by Medicaid in the state.

Please Enter Your Information Here

By submitting this form you agree to be contacted via phone/text/email.

Key Takeaways

Spravato Is Covered: Medicaid typically covers FDA-approved (Food and Drug Administration) esketamine nasal spray for TRD.
IV Ketamine Is Self-Pay: Medicaid plans classify IV infusions as experimental, requiring patients to pay out of pocket.
The Two-Drug Rule: You must prove you have failed at least two different classes of antidepressants to qualify for coverage.
NYRx Program: Pharmacy benefits are now managed through the state-run NYRx program rather than individual managed care plans.
Mandatory Monitoring: All covered treatments must occur in a REMS-certified (Risk Evaluation and Mitigation Strategy) clinic for safety monitoring.

What Is The Difference Between Spravato and IV Ketamine

The primary reason Medicaid covers one form of ketamine and not the other comes down to FDA approval. Spravato, which is a brand-name esketamine nasal spray, has FDA approval specifically for treatment-resistant depression and major depressive disorder with suicidal ideation. Because it has this regulatory stamp, New York Medicaid includes it in its formulary.

In contrast, IV ketamine infusions are used off-label for psychiatric conditions. While there are clinical studies that support the efficacy of IV treatments, Medicaid still classifies them as experimental for depression in 2026. This means that while a provider can administer both, the insurance coverage varies wildly between the two.

Patients often prefer the IV route for its full bioavailability (direct delivery into the bloodstream, avoiding digestive hurdles), but the financial burden falls on the individual. Approximately one-third of patients with MDD meet the criteria for treatment resistance. For these individuals, choosing the covered nasal spray is often the only way to access this life-changing therapy without significant financial strain.

The NYRx Pharmacy Program Standards

In 2026, New York Medicaid beneficiaries utilize the NYRx program for all their prescription drug needs. This state-run program replaced the pharmacy benefit management previously handled by private managed care organizations. This change ensures that coverage for medications like Spravato is consistent across the state, regardless of whether you have Fidelis or Healthfirst.

Under the NYRx program, the drug itself is billed directly to the state. However, the clinical visit where the drug is administered is still billed to your specific Medicaid managed care plan. This split billing can be complex, making it essential to visit a clinic that understands both sides of the transaction.

What Are The Requirements For Treatment-Resistant Depression

To qualify for Medicaid-covered ketamine therapy, a patient must meet the clinical definition of TRD. Treatment-resistant depression isn’t just a subjective feeling; it requires a documented medical history of unsuccessful treatments. New York State Medicaid policy defines TRD as failing at least two different classes of antidepressants.

These antidepressants must have been taken at a therapeutic dose for a minimum of four weeks each. For example, if you tried an SSRI (selective serotonin reuptake inhibitor) and an SNRI (serotonin and norepinephrine reuptake inhibitor) without success, you likely meet the foundational requirement.

Providers must also submit a Prior Authorization request, which is a formal document sent to Medicaid explaining why the treatment is medically necessary.

Clinical Comparison For New York Medicaid Patients

Feature	Spravato	IV Ketamine Infusions	At-Home Oral
NYRx Medicaid Covered	Yes (with Prior Authority)	No (usually self-pay)	No
FDA Approval for Depression	Yes	No (off-label)	No (off-label)
Administration Site	Certified facility	Clinic	At home
Supervised Monitoring	Yes	Yes	No
Typical Out-of-Pocket Cost	$10 – $100 (copay)	$450 – $900 per session	$150 – $350 monthly
Primary Requirement	Fail 2+ antidepressants	Clinical consultation	Clinical consultation
Safety Protocol	REMS-certified	Medical-supervised	Variable

As mentioned, only esketamine nasal spray treatment for eligible patients with TRD is covered by Medicaid in New York. Infusions, which are offered by Ketamine Wellness NY in Queens and Long Island, do not fall under what’s covered. Single IV sessions at Ketamine Wellness NY are priced at $650 (within the typical NYC range), with a $550 introductory rate and a $3,150 six-session package option.

The Role of REMS and Safety Monitoring

Because ketamine can cause temporary side effects like dissociation and increased blood pressure, it must be administered under supervision. The Risk Evaluation and Mitigation Strategy is a safety program required by the FDA. Medicaid will only pay for treatments performed in a REMS-certified facility.

During a Spravato session, patients must stay in the facility for at least two hours for monitoring in case of side effects. You are also required to have a ride home, as driving is prohibited on the day of treatment.

NY Medicaid Managed Care Plans and Spravato Coverage

Under New York’s NYRx pharmacy carve-out, the cost of Spravato (the medication itself) is billed to the state. The clinical visit where Spravato is administered is billed to your individual Medicaid managed care plan. That means two things can vary depending on which plan you have: which REMS-certified clinics are in-network, and what prior authorization paperwork the plan requires.

These are the major Medicaid managed care plans operating in the New York metro area as of 2026:

Fidelis Care. Largest Medicaid MCO in New York. Spravato administration is covered subject to medical-necessity prior authorization through the plan’s behavioral health team.
Healthfirst. Second-largest in NYC and Long Island. Covers Spravato administration with prior authorization. Generally requires documented failure of two antidepressant classes and a behavioral health referral.
MetroPlus Health Plan. Owned by NYC Health and Hospitals. Operates in all five boroughs. Covers Spravato visits under the behavioral health benefit.
EmblemHealth (HIP). Covers Spravato administration through its behavioral health benefit. The in-network REMS-certified clinic network is narrower than Fidelis or Healthfirst.
UnitedHealthcare Community Plan. Spravato visits covered with prior authorization. NYC behavioral health network includes select practices.
Molina Healthcare of New York. Covers Spravato administration with the standard NY Medicaid TRD criteria.

The prescription drug (Spravato) is billed through NYRx regardless of plan, so medication coverage is uniform. The variation is in (a) which REMS-certified clinics are in-network with your plan, and (b) which behavioral health team handles your prior authorization.

Before booking a Spravato consultation, call the number on the back of your Medicaid card and ask three questions:

Is the clinic I am considering in-network with my plan?
What documentation does my plan require for Spravato prior authorization?
Is there a behavioral health referral required before the consultation?

If you have a different Medicaid plan (VillageCareMax, MVP Health Plan, Affinity by Molina), the same NYRx rule applies for the drug, but the visit-side billing path will differ. Confirm with your plan directly.

Ketamine Wellness NY does not currently accept New York Medicaid plans for Spravato administration. If Spravato is the right treatment for you, our team can help you understand the prior authorization process and refer you to in-network Spravato providers in Queens, Long Island, and Manhattan. For our self-pay IV ketamine therapy, see our current pricing at Ketamine Wellness NY.

Does Medicaid Cover Ketamine Therapy In New York? The IV Infusion Alternative In Queens and Long Island

If you and your doctor decide that IV ketamine is a better option than Spravato, you should be prepared for the out-of-pocket costs. Because ketamine infusions remain off-label in 2026 for psychiatric use, Medicaid will almost never reimburse the cost. However, there are patients who find the higher efficacy of IV therapy worth the investment.

Ketamine Wellness NY offers IV ketamine treatment at our Jackson Heights and Great Neck Plaza clinics.

“This is the best place to do ketamine infusions, easily. The staff is excellent, and their professionalism and care is unmatched. This therapy has helped me dramatically improve my anxiety when all other methods of treatment failed me.” – Ketamine Wellness NY patient

Ketamine Wellness NY offers individual sessions at $650 and an introductory promotion of $550 for the first treatment. For patients opting for the induction series, the package of six drips is priced at $3,150 ($525 per session).

If you’re keen to invest in your TRD treatment through IV ketamine, consult with Ketamine Wellness NY today. Our expert teams in Queens and Long Island are ready to assist.

Frequently Asked Questions (FAQs)

How do I prove I have treatment-resistant depression to Medicaid?

To prove treatment-resistant depression, you need records showing that at least two antidepressant classes failed to provide enough improvement. Each medication trial must usually last at least four weeks at a therapeutic dose. Documentation may include prescription history, provider notes, diagnosis records, and response details. These records help Medicaid confirm that standard depression treatments were tried before Spravato coverage is approved.

What is the NYRx program for ketamine therapy?

NYRx is New York’s state-run pharmacy program that pays for certain covered medications. For eligible Medicaid patients, NYRx may cover the Spravato medication itself. Your individual health plan may cover the related doctor visit, in-office administration, and required monitoring. Coverage usually depends on prior authorization, medical documentation, and proof of treatment-resistant depression.

Does Medicaid cover ketamine for depression?

Yes for Spravato, no for IV ketamine. New York Medicaid covers Spravato (esketamine nasal spray) through the NYRx pharmacy program when a patient has documented treatment-resistant depression and has failed at least two different classes of antidepressants at therapeutic doses for at least four weeks each. IV ketamine infusions for depression remain out-of-pocket because they are classified as off-label for psychiatric use.

Does Medicaid cover esketamine?

Yes. Esketamine (brand name Spravato) is FDA-approved for treatment-resistant depression and for major depressive disorder with suicidal ideation. New York Medicaid covers it through the NYRx pharmacy program. Coverage requires prior authorization, documented failure of at least two antidepressant classes, and administration in a REMS-certified clinic. Patient copay typically ranges from $10 to $100 per session depending on the managed care plan.

Will Medicaid cover ketamine therapy for fibromyalgia or chronic pain?

No. New York Medicaid does not cover ketamine infusions for fibromyalgia, neuropathic pain, CRPS, or other chronic pain conditions in 2026. Spravato is only FDA-approved for treatment-resistant depression and major depressive disorder with acute suicidal ideation, so Medicaid coverage does not extend to pain indications. Patients seeking ketamine for chronic pain at Ketamine Wellness NY pay out of pocket.

Does Medicaid cover ketamine nasal spray?

Yes, if the nasal spray is Spravato (esketamine), which is the only FDA-approved intranasal ketamine product. New York Medicaid covers Spravato through NYRx with prior authorization for patients meeting the treatment-resistant depression criteria. Generic compounded ketamine nasal sprays are not FDA-approved and are not Medicaid-covered.

Does Medicaid cover at-home ketamine treatment?

No. New York Medicaid does not cover at-home oral ketamine treatment under any circumstance in 2026. Medicaid coverage for ketamine is restricted to Spravato administered in a REMS-certified clinic under direct medical supervision. The REMS safety program requires in-office monitoring for at least two hours after administration, which is incompatible with at-home delivery.

DISCLAIMER

If you have any medical questions or concerns, please talk to your healthcare provider. The articles on our website are based on information drawn from medical research, societies, and governmental agencies. However, they are not a substitute for professional medical advice, diagnosis, or treatment.